Kura Oncology Reports Strong Clinical Activity and Safety with Darlifarnib + Adagrasib in KRAS G12C-Mutated Solid Tumors
Kura Oncology reported positive Phase 1a data for darlifarnib combined with adagrasib in KRAS G12C-mutated solid tumors, presenting at ASCO 2026. The combination achieved objective response rates of 67% in pancreatic cancer, 50% in non-small cell lung cancer, and 29% in colorectal cancer, with 77% of response-evaluable patients showing tumor shrinkage.
Key figures
- Drug Name
- darlifarnib
- Phase Of Trial
- Phase 1a
- Orr crc
- 29%
- Orr pdac
- 67%
- Orr nsclc
- 50%
- Total patients
- 30
- Tumor shrinkage rate
- 77%
- Response evaluable patients
- 26
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.